{"schema_version":"secwatch.filing_event.v1","accession":"0001711279-25-000088","form_type":"8-K","ticker":"KRYS","cik":"0001711279","company_name":"Krystal Biotech, Inc.","filed_at":"2025-11-03T23:59:59+00:00","discovered_at":"2026-05-14T18:02:40.231523+00:00","generated_at":"2026-05-17T00:54:42.687925+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Krystal Biotech Q3 VYJUVEK revenue $97.8M; label expanded, EU/Japan launches","bullets":["Q3 net product revenue $97.8M (vs $83.8M YoY); net income $79.4M ($2.74 basic EPS); cash $864.2M.","FDA expanded VYJUVEK label to include DEB patients from birth and allow at-home application.","VYJUVEK launched in Germany (Aug), France (Oct), and Japan (Oct); >615 US reimbursement approvals.","FDA granted platform technology designation to HSV-1 vector used in KB801 and other programs.","CF interim data (KB407) expected Q4; KB111 IND cleared for Hailey-Hailey disease; intratumoral KB707 enrollment paused."],"urls":{"canonical":"https://secwatch.observer/filing/0001711279-25-000088","json":"https://secwatch.observer/filing/0001711279-25-000088.json","markdown":"https://secwatch.observer/filing/0001711279-25-000088.md","text":"https://secwatch.observer/filing/0001711279-25-000088.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1711279/000171127925000088/0001711279-25-000088-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1711279/000171127925000088/krys-20251103.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T00:54:42.687925+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}